Welcome To The Sinovac Biotech Ltd HUB China Securities
Sinovac is the only company in the world granted permission to begin clinical trials for a vaccine to prevent SARS
ChinaSecurities News Flash

HOT OFF THE CHINA SECURITIES BLOG ....

1. Canadian Solar (NASDAQ:CSIQ) - 4Q09 net revenues of $287.0 million 

Read More.



2. Gulf Resources (NASDAQ:GFRE) - Net income was $30.6 million, or $1.00 per basic and diluted share, a year-over-year increase of 36.6% from $22.4 million 

Read More.

 

 

3. DEER Consumer Products (NASDAQ:DEER) - Record Revenue of $81.3 million, an increase of 86% from $43.8 million in 2008 

Read More.

Message: Sinovac to Host Conference Call to Report 2009 Third Quarter Financial Results
Admin_profile
ChinaSecurities
Rank: [?]
Administrator
Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Sinovac to Host Conference Call to Report 2009 Third Quarter Financial Results

posted on Nov 10, 09 09:00AM

BEIJING, Nov. 10 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that it will host a conference call on Monday, November 16, 2009 at 9:00 a.m. ET to review the Company's third quarter financial results for the period ended September 30, 2009 and provide an update on recent corporate developments.

To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 12:00 p.m. ET on November 16, 2009 to November 30, 2009 at midnight. To access the replay, please dial 1-877-660-6853 (USA) or 1-201-612-7415 (international) and reference the account number 3055 and the access code 337401.

A live audio webcast of the call will also be available from the Investors section on the corporate web site at http://www.sinovac.com . A webcast replay can be accessed on the corporate website beginning November 16, 2009 and the replay will remain available for 30 days.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products, including Healive® (hepatitis A), Bilive® (combined hepatitis A and B), Anflu® (influenza), Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), and PANFLU.1(TM), Sinovac's H1N1 vaccine, have already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

    For more information, please contact:

Helen G. Yang
Sinovac Biotech Ltd.
Tel: +86-10-8289-0088 x871
Fax: +86-10-6296-6910
Email: info@sinovac.com

Media:
Janine McCargo
The Ruth Group
Tel: +1-646-536-7033
Email: jmccargo@theruthgroup.com

Investors:
Amy Glynn/Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7023/7017
Email: aglynn@theruthgroup.com
scarrington@theruthgroup.com
New Message

Please login to post a reply

Executive Address
Sva - small
Sinovac Biotech Ltd
Welcome to Chinasecurities
May 24, 2009
Stock Quote
Hub Leaders